Format

Send to

Choose Destination
Am J Med Sci. 2010 Jun;339(6):580-1. doi: 10.1097/MAJ.0b013e3181dd1aa5.

Improvement of psoriasis during sunitinib therapy for renal cell carcinoma.

Author information

1
Department of Internal Medicine, University of Utah, Salt Lake City, USA.

Abstract

Sunitinib is an oral tyrosine kinase inhibitor, which is indicated for the treatment of renal cell carcinoma and gastrointestinal stromal tumors. The authors report the case of a patient who underwent treatment for renal cell carcinoma and noted additional benefit by improvement in his psoriatic skin lesions. This may be attributed to the antiangiogenic activity of sunitinib by inhibition of vascular endothelial growth factor receptors.

PMID:
20421784
DOI:
10.1097/MAJ.0b013e3181dd1aa5
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center